09.11.2023 22:30:00
|
Vanda Pharmaceuticals Announces Participation at November 2023 Investor Conferences
WASHINGTON, Nov. 9, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following upcoming investor conferences in November 2023:
The Stifel 2023 Healthcare Conference on Tuesday, November 14, 2023. A corporate presentation is scheduled for 4:10 p.m. Eastern Time.
The Jefferies 2023 London Healthcare Conference on Thursday, November 16, 2023. A corporate presentation is scheduled for 2:00 p.m. Greenwich Mean Time (9:00 a.m. Eastern Time).
The corporate presentations given at the Stifel and Jefferies conferences may be accessed live on Vanda's corporate website, www.vandapharma.com. Investors should click on the Investors tab and follow the links under Recent Events. Investors are advised to go to the conference websites at least 15 minutes early to register, download, and install any necessary software or presentations. Links to the archived conferences will be available on Vanda's website for a period of approximately 30 days.
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-participation-at-november-2023-investor-conferences-301983975.html
SOURCE Vanda Pharmaceuticals Inc.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Vanda Pharmaceuticals IncShsmehr Nachrichten
30.07.24 |
Ausblick: Vanda Pharmaceuticals öffnet die Bücher zum abgelaufenen Quartal (finanzen.net) |